Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab with concurrent radiotherapy for localized muscle-invasive bladder cancer
2017-003159-44Phase 2Active
- Sponsor
- SOGUG
- Start
- Jun 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in muscle-invasive bladder cancer (MIBC), transitional cell carcinoma of the bladder (TCC), sponsored by SOGUG. Started Jun 2018; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2017-003159-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003159-44.